Literature DB >> 22053221

Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis.

Kazuaki Nishio1, Shinji Kashiki, Hideaki Tachibana, Youichi Kobayashi.   

Abstract

AIM: To evaluate the association between genetic polymorphisms and angiotensin converting enzyme inhibitor (ACEI)-related cough, and the race- or ethnicity-related difference in the prevalence of cough attributed to ACEI therapy.
METHODS: We conducted a search in PubMed, EMBASE, Cinahl, and the Cochrane Database without language limitation. A database of 11 studies on ACEI-related cough, with detailed information regarding ACE I/D or bradykinin B(2) receptor polymorphisms, was created. Eligible studies were synthesized using meta-analysis methods, including cumulative meta-analysis. A subgroup analysis was also performed using ethnicity.
RESULTS: Six studies were included on ACE I/D polymorphism (398 Caucasians, 723 East Asians), and three studies were included on bradykinin B(2) receptor polymorphism (300 East Asians). The distribution of ACE genotypes showed significant differences in the entire population (P = 0.004) and in East Asians (P = 0.005) but not in Caucasians (P = 0.23). Allelic frequencies of ACE showed significant differences in East Asians [odds ratio (OR) = 1.49 (1.11-2.02)]. The meta-analysis with a random effects model showed a significant association between ACE allele I/D and ACEI-related cough [random effects (RE) OR = 1.49 (1.11-2.02), P = 0.009] in East Asians, but not in Caucasians [RE OR = 0.90 (0.60-1.35)]. The allelic frequencies of the bradykinin B(2) receptor gene were significantly different [OR = 2.25 (1.42-3.57)]. The distributions of the T/C genotypes of the bradykinin B(2) receptor gene were significantly different (χ(2) = 8.366, P = 0.015). The meta-analyses revealed that there was a significant association between the bradykinin B(2) receptor allele and ACEI-related cough in East Asians [RE OR = 2.29 (1.42-3.69), P = 0.001].
CONCLUSION: ACE I/D and Bradykinin B(2) receptor polymorphisms contributed to the risk of ACEI-related cough in East Asians, but a negative association between ACE I/D polymorphism and ACEI-related cough was observed in Caucasians.

Entities:  

Keywords:  Angiotensin converting enzyme inhibitor; Bradykinin; Cough; Genes; Polymorphism

Year:  2011        PMID: 22053221      PMCID: PMC3206971          DOI: 10.4330/wjc.v3.i10.329

Source DB:  PubMed          Journal:  World J Cardiol


  42 in total

1.  ACE inhibitor cough: a genetic link?

Authors:  W W Yeo; L E Ramsay; A H Morice
Journal:  Lancet       Date:  1991-01-19       Impact factor: 79.321

2.  A DNA polymorphism discovery resource for research on human genetic variation.

Authors:  F S Collins; L D Brooks; A Chakravarti
Journal:  Genome Res       Date:  1998-12       Impact factor: 9.043

3.  Cough from ACE inhibitors.

Authors:  L Karpman
Journal:  Am Heart J       Date:  1988-12       Impact factor: 4.749

4.  A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors.

Authors:  W K Chan; T Y Chan; W K Luk; V K Leung; T H Li; J A Critchley
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Molecular structure and expression of rat bradykinin B2 receptor gene. Evidence for alternative splicing.

Authors:  J B Pesquero; C J Lindsey; K Zeh; A C Paiva; D Ganten; M Bader
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

6.  Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.

Authors:  Y J Lee; J C Tsai
Journal:  Metabolism       Date:  2001-11       Impact factor: 8.694

7.  [No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients].

Authors:  H Okumura; E Nishimura; S Kariya; M Ohtani; K Uchino; T Fukatsu; J Odanaka; T Takahashi; K Watanabe; T Itoh; M Hashiguchi; H Echizen; T Rikihisa
Journal:  Yakugaku Zasshi       Date:  2001-03       Impact factor: 0.302

Review 8.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

Review 9.  Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?

Authors:  P Y Ding; O Y Hu; P E Pool; W Liao
Journal:  J Hum Hypertens       Date:  2000-03       Impact factor: 3.012

10.  Population genetics of the angiotensin-converting enzyme in Chinese.

Authors:  E J Lee
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

View more
  9 in total

Review 1.  African Americans, hypertension and the renin angiotensin system.

Authors:  Sandra F Williams; Susanne B Nicholas; Nosratola D Vaziri; Keith C Norris
Journal:  World J Cardiol       Date:  2014-09-26

2.  Increased risk of pneumonia associated with angiotensin-converting enzyme (CD143) rs4340 polymorphism.

Authors:  Xiaofang Zhang; Fangzhu Liu
Journal:  Clin Exp Med       Date:  2015-05-16       Impact factor: 3.984

3.  Incidence of angiotensin-converting enzyme inhibitor-induced cough in a Malaysian public primary care clinic: A retrospective cohort study.

Authors:  Hou Chan Loo; Fairuz Osman; Siew Lee Ho; Sing Yee An; Yim Mei Au Yong; Ee Ming Khoo
Journal:  Malays Fam Physician       Date:  2022-03-22

4.  Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis.

Authors:  Ya-Feng Li; Xiao-Ming Zhu; Fan Liu; Chuan-Shi Xiao; Yun-Fei Bian; Hong Li; Jun Cai; Rong-Shan Li; Xin-Chun Yang
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

Review 5.  Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis.

Authors:  Ye Yuan; Lin Meng; Yan Zhou; Na Lu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  False-negative diagnosis of high anion gap in patients with end-stage kidney disease.

Authors:  You Komatsuzaki; Masato Ikeda; Akihiro Shimizu; Nanae Matsuo; Yukio Maruyama; Takashi Yokoo; Hiroyuki Yamamoto; Nobuhiko Joki; Ryoichi Ando; Daijo Inaguma; Toshihiko Yamaka; Masaaki Nakayama; Fumihiko Koiwa; Shinya Kawamoto; Shigeo Negi; Takashi Shigematsu
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

7.  Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan.

Authors:  Fumiki Yoshihara; Hiroshi Ohtsu; Michikazu Nakai; Shinya Tsuzuki; Kayoko Hayakawa; Mari Terada; Nobuaki Matsunaga; Satoshi Yasuda; Hisao Ogawa; Norio Ohmagari
Journal:  J Cardiol       Date:  2022-04-08       Impact factor: 2.974

8.  Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.

Authors:  Jianmin Yang; Yunhan Zhao; Panpan Hao; Xiao Meng; Mei Dong; Ying Wang; Yun Zhang; Cheng Zhang
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

Review 9.  Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.

Authors:  Hong Wang; Kun Zhang; Haifeng Qin; Lin Yang; Liyu Zhang; Yanyan Cao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.